Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/29661
Başlık: | Synaptogenesis: Modulation by availability of membrane phospholipid precursors |
Yazarlar: | Uludağ Üniversitesi/Tıp Fakültesi/Eczacılık Anabilim Dalı. 0000-0003-2918-5064 Cansev, Mehmet M-9071-2019 8872816100 |
Anahtar kelimeler: | Neurosciences & neurology Synaptogenesis Uridine Choline Docosahexaenoic acid Cognition Alzheimer's disease Cdp-choline levels Alzheimers-disease Fatty-acid Dietary supplementation Functional expression Brain phospholipids Synaptic proteins Learning-ability Plasma choline |
Yayın Tarihi: | 24-May-2016 |
Yayıncı: | Humana Press |
Atıf: | Cansev, M. (2016). "Synaptogenesis: Modulation by availability of membrane phospholipid precursors". NeuroMolecular Medicine, 18(3), 426-440. |
Özet: | Phospholipids are the main constituents of brain membranes. Formation of new membranes requires that uridine, the omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA), and choline, the three circulating precursors of major phospholipids, interact via the Kennedy pathway. Supplementation of laboratory rodents with uridine, DHA and choline enhances the amount of brain membranes as well as synaptic proteins and increases the number of dendritic spines, the essential cytological precursor of new synapses. Hence, the newly formed membranes are utilized for synaptogenesis which underlies increased synaptic functioning evidenced by enhanced neurotransmission and cognition. In addition, this supplementation ameliorates the degeneration in a rat model of Parkinson's disease and mouse models of Alzheimer's disease (AD) when used in combination with several vitamins and cofactors. Hence, accumulating evidence shows that increasing the availability of phospholipid precursors, vitamins and cofactors to the brain through dietary supplementation enhances the formation of new synapses and provides protection under neurodegenerative conditions. The combination has been tested in clinical trials and a medication has been marketed for early-stage AD patients. |
URI: | https://doi.org/10.1007/s12017-016-8414-x https://link.springer.com/article/10.1007/s12017-016-8414-x http://hdl.handle.net/11452/29661 |
ISSN: | 1535-1084 1559-1174 |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.